# US 2010/0303905 A1 · Orally Disintegrating Tablet Compositions of Lamotrigine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303905 A1
- Document ID: US20100303905A1
- Status: Published application
- Kind: A1
- Application number: 12/628,677
- Filed: 2009-12-01
- Published: 2010-12-02
- Earliest claimed: 2007-07-02
- Assignees: Aptalis Pharmatech, Inc.
- Inventors: Gopi M. Venkatesh; Nehal H. Vyas; Michael Gosselin; Jin-Wang Lai
- Web page: https://patentgrep.com/patent/US20100303905A1

## CPC

- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 9/2095: {Tabletting processes}
- A61K 9/5005: {Wall or coating material}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 9/5042: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
- A61K 9/5047: {Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}
- A61K 9/5089: {Processes}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61K 9/0007: {Effervescent (A61K9/0065 takes precedence)}
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.

## Claims

### Claim 1

An orally dissolving or disintegrating (ODT) composition comprising a therapeutically effective amount of lamotrigine, wherein after administration said composition substantially disintegrates in the oral cavity of a patient and provides a lamotrigine release profile which is substantially the same as the lamotrigine release profile of an immediate release lamotrigine composition.

### Claim 2 (depends on 1)

The ODT composition of claim 1, wherein the composition substantially disintegrates within about 60 seconds after administration in the oral cavity of the patient.

### Claim 3 (depends on 2)

The ODT composition of claim 2, wherein the composition substantially disintegrates within about 30 seconds after administration in the oral cavity of the patient.

### Claim 4 (depends on 1)

The ODT composition of claim 1, wherein the composition disintegrates within about 30 seconds when tested by the <USP 701> Disintegration Test.

### Claim 5 (depends on 1)

The ODT composition of claim 1, wherein the composition releases about 70% or more of the lamotrigine in 30 min when tested for dissolution using United States Pharmacopoeia Apparatus 2 (paddles @ 75 rpm in 900 mL of 0.01N HCl buffer).

### Claim 6 (depends on 1)

The ODT composition of claim 1, further comprising additional pharmaceutically acceptable ingredients selected from the group consisting of a filler, a flavor, a sweetener, a colorant, a disintegrant, and combinations thereof.

### Claim 7 (depends on 6)

The ODT composition of claim 6, comprising lamotrigine in the form of lamotrigine-containing particles coated with a taste-masking layer; and
rapidly dispersing granules comprising a disintegrant and a sugar alcohol and/or a saccharide.

### Claim 8 (depends on 6)

The ODT composition of claim 6, comprising lamotrigine which is not coated with a taste-masking layer; and
rapidly dispersing granules comprising a disintegrant and a sugar alcohol and/or a saccharide.

### Claim 9 (depends on 7)

The ODT composition of claim 7, wherein the lamotrigine-containing particles are in the form of a lamotrigine crystalline material, granules, or drug-layered beads comprising lamotrigine, and the lamotrigine-containing particles are coated with a taste-masking layer.

### Claim 10 (depends on 7)

The ODT composition of claim 7, wherein secondary lamotrigine-containing particles have an average particle size of about 400 μm or less, and primary particles of lamotrigine have an average particle size of about 1-300 μm.

### Claim 11 (depends on 10)

The ODT composition of claim 10, wherein secondary lamotrigine-containing particles have an average particle size of about 300 μm or less and primary particles of lamotrigine have an average particle size of about 1-100 μm.

### Claim 12 (depends on 10)

The ODT composition of claim 10, wherein secondary lamotrigine-containing particles have an average particle size of about 100 μm or less and primary particles of lamotrigine have an average particle size of about 1-50 μm.

### Claim 13 (depends on 7)

The ODT composition of claim 7, wherein secondary lamotrigine-containing particles have an average particle size of about 400 μm or less, primary particles of the lamotrigine have an average particle size of about 1-50 μm; and
the rapidly dispersing granules have an average particle size of about 400 μm or less, and primary particles of the sugar alcohol and/or saccharide have an average particle size of about 1-30 μm.

### Claim 14 (depends on 1)

The ODT composition of claim 1, wherein the taste-masking layer comprises a water-insoluble taste-masking polymer or a water-insoluble taste-masking polymer in combination with a water-soluble or gastrosoluble pore former.

### Claim 15 (depends on 1)

The ODT composition of claim 1, wherein after the composition disintegrates in the oral cavity, the disintegrated composition has a mouthfeel rating of 5 or higher on a mouthfeel/aftertaste scale of: 1(very bitter)—5 (further taste-masking needed)—10 (pleasant taste).

### Claim 16 (depends on 9)

The ODT composition of claim 9, wherein the lamotrigine particles are drug-layered beads comprising an inert core and a drug layer coated with a taste-masking layer, and the core is a sugar sphere or a cellulose sphere.

### Claim 17 (depends on 9)

The ODT composition of claim 9, wherein the taste-masking layer comprises a water-insoluble taste masking polymer.

### Claim 18 (depends on 17)

The ODT composition of claim 17, comprising about 5% to about 30% by weight of lamotrigine particles.

### Claim 19 (depends on 17)

The ODT composition of claim 17, wherein the water-insoluble taste-masking polymer is selected from the group consisting of ethylcellulose, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, neutral methacrylic ester copolymer, ammonio-methacrylate copolymers and mixtures thereof.

### Claim 20 (depends on 17)

The ODT composition of claim 17, wherein the lamotrigine-containing particles comprise a water-insoluble taste-masking polymer in combination with a water-soluble pore former, and the water-soluble pore former is selected from the group consisting of sucrose, sodium chloride, povidone, and mixtures thereof.

### Claim 21 (depends on 17)

The ODT composition of claim 17, wherein the lamotrigine-containing particles comprise a water-insoluble taste-masking polymer in combination with a gastrosoluble pore former, and the gastrosoluble pore former is selected from the group consisting of calcium carbonate, magnesium hydroxide, and mixtures thereof.

### Claim 22 (depends on 20)

The ODT composition of claim 20, wherein the ratio of water-insoluble polymer/water-soluble pore former ranges from about 90/10 to about 50/50.

### Claim 23 (depends on 21)

The ODT composition of claim 21, wherein the ratio of a water-insoluble taste-masking polymer/gastrosoluble pore former ranges from about 90/10 to about 50/50.

### Claim 24 (depends on 17)

The ODT composition of claim 17, wherein the water-insoluble taste-masking polymer is ethylcellulose having a viscosity of about 90-110 cps when tested in an Ubbelohde viscometer as a 5 weight % 80:20 toluene/ethanol solution at 25° C.

### Claim 25 (depends on 7)

The ODT composition of claim 7, wherein the disintegrant and the sugar alcohol and/or saccharide are present at a ratio of sugar alcohol and/or saccharide to disintegrant of from about 90/10 to about 99/1.

### Claim 26 (depends on 6)

The ODT composition of claim 6, wherein the composition comprises a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate, crosslinked carboxymethyl cellulose of sodium, low-substituted hydroxypropylcellulose and mixtures thereof.

### Claim 27 (depends on 6)

The ODT composition of claim 6, wherein the composition comprises a sugar alcohol selected from the group consisting of mannitol, xylitol, sorbitol, maltitol, maltitol and mixtures thereof.

### Claim 28 (depends on 6)

The ODT composition of claim 6, wherein the composition comprises a saccharide selected from the group consisting of lactose, sucrose, and maltose and mixtures thereof.

### Claim 29 (depends on 1)

A method of preparing the ODT composition of claim 1, comprising granulation of a mixture comprising lamotrigine, a filler, a polymer binder and/or a disintegrant, and forming an ODT composition.

### Claim 30 (depends on 29)

The method of claim 29, wherein the composition comprises one or more pharmaceutically acceptable ingredients selected from the group consisting of a filler, a flavor, a sweetener, a colorant, a disintegrant, and combinations thereof.

### Claim 31 (depends on 1)

A method of preparing the ODT composition of claim 1, comprising:
(a) coating particles comprising lamotrigine with a taste-masking layer;
(b) preparing granules comprising a disintegrant and a sugar alcohol and/or a saccharide;
(c) mixing the coated particles of step (a) with the granules of step (b) and optionally other pharmaceutically acceptable ingredients; and
(d) compressing the blend of step (c) into tablets.

### Claim 32 (depends on 31)

The method of claim 31, wherein the particles comprising lamotrigine have an average particle size of not more than about 400 μm and the rapidly dispersing granules have an average particle size of not more than about 400 μm.

### Claim 33 (depends on 31)

The method of claim 31, wherein the particles comprising lamotrigine are in the form of lamotrigine crystalline material having an average particle size of about 1-200 μm.

### Claim 34 (depends on 33)

The method of claim 33, wherein the lamotrigine crystalline material has an average particle size of about 1-50 μm.

### Claim 35 (depends on 31)

The method of claim 31, wherein the particles comprising lamotrigine are microgranules of lamotrigine in combination with a polymeric binder, a disintegrant, and a hydrophilic filler/diluent.

### Claim 36 (depends on 31)

The method of claim 31, wherein the particles comprising lamotrigine are drug-layered beads comprising lamotrigine and a polymeric binder, layered onto an inert core.

### Claim 37 (depends on 31)

The method of claim 31, wherein said coating step is coacervation.

### Claim 38 (depends on 31)

The method of claim 31, wherein said coating step is carried out in a fluid bed coating equipment.

### Claim 39 (depends on 31)

The method of claim 31, wherein the taste-masking layer comprises a water-insoluble taste-masking polymer selected from the group consisting of ethylcellulose, cellulose acetate, cellulose acetate butyrate, polyvinyl acetate, neutral methacrylic ester copolymer, ammonio-methacrylate copolymers and mixtures thereof.

### Claim 40 (depends on 39)

The method of claim 39 wherein the taste-masking layer further comprises a water-soluble or gastrosoluble pore-former selected from the group consisting of sucrose, sodium chloride, povidone, and calcium carbonate.

### Claim 41 (depends on 31)

The method of claim 31, wherein said compressing is carried out with tablet press equipped with an external lubrication system to pre-lubricate the dies and punches.

### Claim 42 (depends on 41)

The method of claim 41, wherein step (a) further comprises blending the particles comprising lamotrigine with a lubricant; and
said compression is carried out using a rotary tablet press.

### Claim 43 (depends on 1)

A method of treating a mood disorder, or treating or preventing seizures comprising administering to a patient in need thereof a therapeutically effective amount of the ODT composition of claim 1, wherein said administration of the ODT composition provides a lamotrigine release profile in the patient which is substantially the same as the lamotrigine release profile of an immediate release lamotrigine composition.

### Claim 44 (depends on 43)

The method of claim 43, wherein the mood disorder is a bipolar disorder.

### Claim 45 (depends on 1)

A method of increasing patient compliance with a method of treating a bipolar disorder comprising administering the ODT composition of claim 1, wherein the increase in patient compliance is compared to a non-ODT lamotrigine composition.

### Claim 46 (depends on 45)

The method of claim 45, wherein the ODT composition dissolves or disintegrates in the patient's oral cavity before the patient can expel the composition.

### Claim 47 (depends on 46)

The method of claim 46, wherein the ODT composition substantially disintegrates in the patient's oral cavity within about 60 seconds.

### Claim 48 (depends on 46)

The method of claim 46, wherein the ODT composition substantially disintegrates in the patient's oral cavity within about 30 seconds.

### Claim 49 (depends on 47)

The method of claim 47, wherein the ODT composition substantially disintegrates in the patient's oral cavity within about 30 seconds.

### Claim 50 (depends on 49)

The method of claim 49, wherein the ODT composition delivers at least about 70% of the total dose of lamotrigine upon entering the stomach of the patient.

### Claim 51 (depends on 49)

The method of claim 49, wherein the ODT composition delivers at least about 90% of the total dose of lamotrigine upon entering the stomach of the patient.

### Claim 52 (depends on 49)

The method of claim 49, wherein the ODT composition delivers at least about 95% of the total dose of lamotrigine upon entering the stomach of the patient.
